Stem cells – what is the evidence: Mesenchymal stem cells

spotlight topic:

Mesenchymal stem cells

Published 26 February 2024

Mesenchymal stem cells are naturally present in various tissues, including bone marrow, adipose tissue (fat), and umbilical cord tissue. They are multipotent meaning that they can develop into a range of cell types, often related to their tissue of origin.

The activation of mesenchymal stem cells may be referred to as licensing, not to be confused with the product licensing of medicinal products.

It is also important to consider the evidence regarding the advantages and disadvantages of allogenic versus autologous stem cells.

  • Barrachina, L. et al. (2018) Practical considerations for clinical use of mesenchymal stem cells: From the laboratory to the horse. The Veterinary Journal, 238, pp. 49-57.
  • Gugjoo, M.B. and Sharma, G.T. (2019) Equine mesenchymal stem cells: properties, sources, characterization, and potential therapeutic applications. Journal of Equine Veterinary Science, 72, pp. 16-27.
  • Prządka, P. et al. (2021) The role of mesenchymal stem cells (MSCs) in veterinary medicine and their use in musculoskeletal disorders. Biomolecules, 11 (8), p.1141.
  • Cequier, A. et al. (2021) The usefulness of mesenchymal stem cells beyond the musculoskeletal system in horses. Animals, 11 (4), no. 931.
  • Baouche, M. et al. (2023) Mesenchymal stem cells: Generalities and clinical significance in feline and canine medicine. Animals, 13 (12), no. 1903.
  • Colbath, A.C. et al. (2020) Mesenchymal stem cells for treatment of musculoskeletal disease in horses: Relative merits of allogeneic versus autologous stem cells. Equine Veterinary Journal, 52 (5), pp. 654-663.
  • Ursini, T.L. et al. (2019) Retrospective analysis of local injection site adverse reactions associated with 230 allogenic administrations of bone marrow‐derived mesenchymal stem cells in 164 horses. Equine Veterinary Journal, 51 (2), pp. 198-205.
  • Koch, D.W. and Schnabel, L.V. (2023) Mesenchymal stem cell licensing: enhancing MSC function as a translational approach for the treatment of tendon injury. American Journal of Veterinary Research, 84 (10), pp. 1-8.
  • Ivanovska, A. et al. (2022) Manufacturing mesenchymal stromal cells for the treatment of osteoarthritis in canine patients: challenges and recommendations. Frontiers in Veterinary Science, 9, no. 897150.
  • Armitage, A.J. et al. (2023) Efficacy of autologous mesenchymal stromal cell treatment for chronic degenerative musculoskeletal conditions in dogs: A retrospective study. Frontiers in Veterinary Science, 9, no. 1014687.
  • Moloney, M. (2022) In dogs with osteoarthritis, is intra-articular allogenic mesenchymal stem cell therapy more effective than placebo effect? Veterinary Evidence, 7 (3).
  • Nekouei, O. et al. (2024) Effectiveness of mesenchymal stem cell therapy in cats with chronic gingivostomatitis. Veterinary Evidence, 9 (1).

Claiming CPD for reading inFOCUS articles

Reading and reflecting on articles can count towards your CPD, and we have a template to help you with the process.

Online full-text available to Library members

A range of library membership packages is available and MRCVS vets and RVNs can join the library for a heavily subsidised, annual fee.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.